Cómo citar
Resumen
El síndrome miasténico de Lambert Eaton es una patología autoinmune paraneoplásica asociada mayormente a cáncer de pulmón, que se manifiesta con afectación de la unión neuromuscular y disfunciones autonómicas. Se presenta el caso de una paciente femenina de 58 años quien fue diagnosticada con cáncer de pulmón de células pequeñas y que posteriormente presentó la tríada clásica de síndrome miasténico de Lambert Eaton (debilidad proximal de miembros inferiores, disfunción autonómica e hiporreflexia). Se abordó mediante pruebas neurofisiológicas (electromiografía), confirmando su diagnóstico en asociación con el cuadro clínico. El caso presentado a continuación destaca la asociación de neoplasias pulmonares con el diagnóstico de síndrome miasténico de Lambert Eaton y la mejoría de los síntomas gracias al tratamiento sintomático y oncológico.
Palabras clave
Citas
Todisco V, Cirillo G, Capuano R, d'Ambrosio A, Tedeschi G, Gallo A. Stimulated single-fiber electromyography (sSFEMG) in Lambert-Eaton syndrome. Clinical Neurophysiology Practice. 2018; 3:148-150. https://doi.org/10.1016/j.cnp.2018.07.001
Ruelle L, Bentea G, Sideris S, El Koulali M, Holbrechts S, Lafitte J et al. Autoimmune paraneoplastic syndromes associated to lung cancer: A systematic review of the literature Part 4: Neurological paraneoplastic syndromes, involving the peripheral nervous system and the neuromuscular junction and muscles. Lung Cancer. 2017; 111:150-163. https://doi.org/10.1016/j.lungcan.2017.07.025
Sweeney L, Howe T. Paraneoplastic syndromes. Medicine. 2020; 48(2):144-147. https://doi.org/10.1016/j.mpmed.2019.11.015
Tas D. Paraneoplastic Syndromes in Lung Cancer. Lung Cancer - Strategies for Diagnosis and Treatment. 2018.
https://doi.org/10.5772/intechopen.79127
Bukhari S, Soomro R, Fawwad S, Alvarez C, Wallach S. Adenocarcinoma of Lung Presenting as Lambert-Eaton Myasthenic Syndrome. Journal of Investigative Medicine High Impact Case Reports. 2017; 5(3). https://doi.org/10.1177/2324709617721251
Matsumoto H, Ugawa Y. Lambert-Eaton Myasthenic Syndrome: A Review. Journal of General and Family Medicine. 2016; 17(2): 138-143. DOI: https://doi.org/10.14442/jgfm.17.2_138
Abenroth D, Smith A, Greenlee J, Austin S, Clardy S. Lambert-Eaton myasthenic syndrome: Epidemiology and therapeutic response in the national veterans affairs population. Muscle & Nerve. 2017; 56(3): 421-426. https://doi.org/10.1002/mus.25520
Schoser B, Eymard B, Datt J, Mantegazza R. Lambert-Eaton myasthenic syndrome (LEMS): a rare autoimmune presynaptic disorder often associated with cancer. Journal of Neurology. 2017; 264: 1854-1863. https://doi.org/10.1007/s00415-017-8541-9
Agrawal K, Agrawal N. Lambert-Eaton Myasthenic Syndrome Secondary to Nivolumab and Ipilimumab in a Patient with Small-Cell Lung Cancer. Case Reports in Neurological Medicine. 2019. https://doi.org/10.1155/2019/5353202
Harper C, Lennon V. Lambert-Eaton Syndrome. Current Clinical Neurology. 2018; 221-237. https://doi.org/10.1007/978-3-319-73585-6_14
Zhang K, Liu W, Li Y, Zhang K, Gao X, Wang J. Mediastinal small cell cancer associated with Lambert-Eaton myasthenic syndrome: A case report. Experimental and Therapeutic Medicine. 2015; 10(1): 117-120. https://doi.org/10.3892/etm.2015.2454
Wang A, Zhang X, Yi J, Zhu M, Zhang Y. Successful treatment of advanced lung adenocarcinoma complicated with Lambert‐Eaton myasthenic syndrome: A case report and literature review. Thoracic Cancer. 2020; 11(5): 1334-1338. https://doi.org/10.1111/1759-7714.13385
Katyal N, Govindarajan R. Pure Ocular Weakness as the Initial Manifestation of Lambert-Eaton Myasthenic Syndrome. Cureus. 2017; 9(12). https://doi.org/10.7759/cureus.2007
Ivanovski T, Miralles F. Lambert-Eaton Myasthenic syndrome: early diagnosis is key. Degenerative Neurological and Neuromuscular Disease. 2019; 9: 27-37. https://doi.org/10.2147/DNND.S192588
Motomura M, Nakata R, Shiraishi H. Lambert-Eaton myasthenic syndrome: Clinical review. Clinical and Experimental Neuroimmunology. 2016; 7(3): 238-245. https://doi.org/10.1111/cen3.12326
Merino-Ramírez M, Bolton C. Review of the Diagnostic Challenges of Lambert-Eaton Syndrome Revealed Through Three Case Reports. Canadian Journal of Neurological Sciences. 2016; 43(5): 635-647. https://doi.org/10.1017/cjn.2016.268
Hajela R, Huntoon K, Atchison W. Lambert-Eaton syndrome antibodies target multiple subunits of voltage-gated Ca2+channels. Muscle & Nerve. 2014; 51(2): 176-184. https://doi.org/10.1002/mus.24295
Anwar A, Jafri F, Ashraf S, Jafri M, Fanucchi M. Paraneoplastic syndromes in lung cancer and their management. Annals of Translational Medicine. 2019; 7(15): 359-359. https://doi.org/10.21037/atm.2019.04.86
Cetin H, Vincent A. Pathogenic Mechanisms and Clinical Correlations in Autoimmune Myasthenic Syndromes. Seminars in Neurology. 2018; 38(3): 344-354. https://doi.org/10.1055/s-0038-1660500
Kwiatkowski S, Kolasińska K, Knap B, Przystupski D, Kotowski K, Bartosik W et al. An overview of paraneoplastic neurological syndromes - pathophysiology and clinical insight. World Scientific News. 2018; 108: 87-98.Disponible en: https://www.researchgate.net/publication/327221613_An_overview_of_paraneoplastic_neurological_syndromes_-_pathophysiology_and_clinical_insight
Li C, Wang X, Sun L, Deng H, Han Y, Zheng W. Anti‐SOX1 antibody‐positive paraneoplastic neurological syndrome presenting with Lambert‐Eaton myasthenic syndrome and small cell lung cancer: A case report. Thoracic Cancer. 2019; 11(2): 465-469. https://doi.org/10.1111/1759-7714.13290
Kesner V, Oh S, Dimachkie M, Barohn R. Lambert-Eaton Myasthenic Syndrome. Neurologic Clinics. 2018; 36(2): 379-394. https://doi.org/10.1016/j.ncl.2018.01.008
Liu Y, Xi J, Zhou L, Wu H, Yue D, Zhu W et al. Clinical characteristics and long term follow-up of Lambert-Eaton myasthenia syndrome in patients with and without small cell lung cancer. Journal of Clinical Neuroscience. 2019; 65: 41-45. https://doi.org/10.1016/j.jocn.2019.04.003
Anwar A, Saleem S, Ahmed M, Ashraf S, Ashraf S. Recent Advances and Therapeutic Options in Lambert-Eaton Myasthenic Syndrome. Cureus. 2019; 11(8). https://doi.org/10.7759/cureus.5450